Assessment of Cardiovascular Risk with the Use of Androgen Deprivation Therapy for Prostate Cancer - Matthew Roe


UroToday is excited to host a lecture from a leading cardiologist’s perspective, Dr. Matthew Roe from Duke Clinical Research Institute.  Dr. Roe’s discussion features the topics: atherosclerotic plaque formation and plaque instability and incidences of prostate cancer and cardiovascular events.  In addition, cardiovascular risks with androgen deprivation therapy, GNRH antagonists and GnRH agonists.


Biography:
Matthew T. Roe, MD, MHS

Faculty Director, Global Outcomes Commercial Megatrials
DCRI Fellowship Program Director
Associate Professor of Medicine


Duke Clinical Research Institute
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe